{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:24:00Z","timestamp":1768260240291,"version":"3.49.0"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,10,12]],"date-time":"2010-10-12T00:00:00Z","timestamp":1286841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:p><jats:bold>Aim:\u2002<\/jats:bold> Patients with panic disorder (PD) might be sensitive to the stimulating effects of selective serotonin reuptake inhibitors (SSRI), thus requiring low dosages at treatment initiation. The aim of the present study was to assess eventual differences in terms of effectiveness and tolerability between a slow up\u2010titration with paroxetine and a standard one.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> In an open randomized, multicenter, primary\u2010care study, 60 patients (44 women and 16 men) with PD with or without agoraphobia were enrolled and randomized to receive a slow up\u2010titration with paroxetine (increments of 2.5\u2003mg\/day every 2\u2003days) or a standard one (increments of 10\u2003mg\/day every week) up to a maximum daily dose of 20\u2003mg. Repeated\u2010measures <jats:sc>anova<\/jats:sc> on sub\u2010items scores of the Panic Attack Anticipatory Anxiety Scale (PAAS) and Dosage Record and Treatment Emergent Symptom Scale (DOTES), respectively, used as outcome measures of effectiveness and tolerability, were performed. Significance level was set at 0.05 and it was not corrected.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold>  <jats:sc>anova<\/jats:sc> showed no differences between the two treatments in terms of effectiveness and tolerability. Post hoc analysis found only one significant difference in the intensity of spontaneous panic attacks (Panic and Anticipatory Anxiety Scale) in the first 9\u2003days of treatment between the two treatment groups, which was that this item was less intense in the slow\u2010titration group (treatment effect: <jats:italic>F<\/jats:italic>\u2003=\u20034.89, <jats:italic>P<\/jats:italic>\u2003=\u20030.03, effect size\u2003=\u20030.1).<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Present findings suggest only a small superiority for a slow up\u2010titration regimen of paroxetine compared to a standard one in the first 9\u2003days of treatment but no differences at end\u2010point.<\/jats:p>","DOI":"10.1111\/j.1440-1819.2010.02136.x","type":"journal-article","created":{"date-parts":[[2010,10,12]],"date-time":"2010-10-12T09:59:23Z","timestamp":1286877563000},"page":"612-619","source":"Crossref","is-referenced-by-count":19,"title":["Slow vs standard up\u2010titration of paroxetine in the treatment of panic disorder: A prospective randomized trial"],"prefix":"10.1111","volume":"64","author":[{"given":"Massimiliano","family":"Buoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Dell'Osso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica Francesca","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,10,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370905400209"},{"key":"e_1_2_6_3_2","first-page":"38","article-title":"Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project","volume":"420","author":"Alonso J","year":"2004","journal-title":"Acta Psychiatr. Scand."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.617"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.593"},{"key":"e_1_2_6_6_2","first-page":"345","article-title":"Duration of untreated illness in panic disorder: a poor outcome risk factor?","volume":"1","author":"Altamura AC","year":"2005","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2007.03.006"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-006-0063-6"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.04.012"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/15622970209150621"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881105059253","article-title":"Evidence\u2010based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology","volume":"9","author":"Baldwin DS","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S1224"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.04.017"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/msj.20041"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2002.02255.x"},{"key":"e_1_2_6_16_2","volume-title":"Practice Guideline for the Treatment of Patients with Panic Disorder","author":"Stein MB","year":"2009"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0105"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855010-00007"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-4-16"},{"key":"e_1_2_6_20_2","first-page":"250","article-title":"Causes of failure in psychopharmacological treatment of anxiety disorder","volume":"27","author":"Segu\u00ed J","year":"1999","journal-title":"Actas Esp. Psiquiatr."},{"key":"e_1_2_6_21_2","first-page":"1","article-title":"The 2\u2010year prognosis of panic episodes in the general population","volume":"29","author":"Batelaan NM","year":"2009","journal-title":"Psychol. Med."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0047.2004.00347.x"},{"key":"e_1_2_6_23_2","unstructured":"EaddyM SheehanD SarnesM ReganT MauchR.SSRI utilization patterns and the economic consequences of early discontinuation.2004. Poster presented at 157th annual Meeting of the American psychiatric Association New York NY."},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199501000-00006"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.048371"},{"key":"e_1_2_6_26_2","first-page":"1906","volume-title":"Kaplan and Sadock's Comprehensive Textbook of Psychiatry","author":"Stein MB","year":"2005"},{"key":"e_1_2_6_27_2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM\u2010IV)","author":"American Psychiatric Association","year":"1994"},{"key":"e_1_2_6_28_2","volume-title":"Structured Clinical Interview Diagnostic (SCID) for DSM\u2010IV Axis I Disorders \u2013 Clinician Version","author":"First MB","year":"1997"},{"key":"e_1_2_6_29_2","volume-title":"Sheehan Anxiety and Panic Attack Scales","author":"Sheehan DV","year":"1983"},{"key":"e_1_2_6_30_2","volume-title":"DOTES: Dosage Record and Treatment Emergent Symptom Scale, in ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbtep.2006.01.002"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1806-37132009000700012"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2009.07.012"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e318064579f"},{"key":"e_1_2_6_35_2","volume-title":"Lexicon of Psychiatry, Neurology and the Neurosciences","author":"Frank J","year":"2000"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200012000-00007"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.12.036"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1157\/13079865"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2007.03.004"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1819.2010.02136.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1819.2010.02136.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T03:22:06Z","timestamp":1697253726000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1819.2010.02136.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1111\/j.1440-1819.2010.02136.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1819.2010.02136.x","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,12]]}}}